The AI Biotech With 37,000 Virtual Employees Just Published in Science
Stanford's 37,000-agent Virtual Biotech mined 55,984 clinical trials and independently designed a lung cancer drug strategy Merck was already pursuing.
AI Protein Design Cracks Biotech's Biggest Bottleneck: Delivery
German scientists used generative AI to design Synthetic Transfer Vehicles, protein shells that carried RNA into cells more efficiently than the lipid nanoparticles they tested and delivered a CRISPR edit in a pig.
AI Beat the Lab at Antibody Design, But Just Once
The first blinded, wet-lab-validated benchmark for AI antibody design just landed in Nature Biotechnology. Here is what the models got right, and wrong.
AI Discovered a Novel Drug Target; and Pharma Bought It
Genentech validated the first AI-discovered neuroscience drug target from its $12B Recursion partnership. A proof point the AI-drug discovery field needed.
AI Redesigned CRISPR's Molecular Scissors, and They Beat Nature's
Jennifer Doudna's lab used an AI protein-design model to build a synthetic gene-editing enzyme, SynTnpB, that edits human cells nearly twice as efficiently as the natural version. Here is what the Science paper actually shows, and what it does not.